Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.
Steven D Linton, Teresa Aja, Peter R Allegrini, Thomas L Deckwerth, Jose-Luis Diaz, Bastian Hengerer, Julia Herrmann, Kathy G Jahangiri, Joerg Kallen, Donald S Karanewsky, Steven P Meduna, Kip Nalley, Edward D Robinson, Silvio Roggo, Giorgio Rovelli, Andre Sauter, Robert O Sayers, Albert Schmitz, Robert Smidt, Robert J Ternansky, Kevin J Tomaselli, Brett R Ullman, Christoph Wiessner, Joe C Wu
Index: Bioorg. Med. Chem. Lett. 14(10) , 2685-91, (2004)
Full Text: HTML
Abstract
Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein.
Related Compounds
Related Articles:
2010-08-01
[Environ. Toxicol. 25(4) , 327-32, (2010)]
1991-04-01
[Vet. Hum. Toxicol. 33(2) , 166-8, (1991)]
2000-08-01
[Arch. Environ. Contam. Toxicol. 39(2) , 233-42, (2000)]
2007-03-01
[Toxicol. Sci. 96(1) , 154-61, (2007)]
2011-05-01
[Pest Manag. Sci. 67(5) , 507-13, (2011)]